Sugi Predict

Sugi Predict / Compounds / SCHEMBL14616181

SCHEMBL14616181

SCHEMBL14616181

Cc1ccccc1CN=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 1/20 0.46
▸ CTBP2 P56545 1/20 0.44
▸ PTGS1 P23219 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ TSHR P16473 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CHRM2 P08172 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ KMT2A Q03164 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ HTT P42858 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP2A13 Q16696 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297196 0.82 TAAR1 (0.52) TAAR1CTBP2PTGS1PTGS2TSHR
SCHEMBL8865803 0.82 ESR1 (0.41) TAAR1CTBP2PTGS2TSHRMAPT
SCHEMBL18508126 0.79 MPO (0.35) TAAR1CTBP2PTGS1PTGS2TSHR
SCHEMBL13272189 0.78 HTR1A (0.41) TAAR1CTBP2HPGDALDH1A1MAPT
SCHEMBL3482967 0.78 TAAR1 (0.48) TAAR1CTBP2PTGS1PTGS2TSHR
SCHEMBL20381848 0.78 GABRA1 (0.42) ALDH1A1MAPTHTTLMNAGAA
SCHEMBL6582 0.77 TAAR1 (0.43) TAAR1CTBP2PTGS1PTGS2TSHR
SCHEMBL15304790 0.76 TAAR1 (0.46) TAAR1CTBP2PTGS1PTGS2TSHR
SCHEMBL8244140 0.76 TAAR1 (0.42) TAAR1CTBP2PTGS1PTGS2TSHR
SCHEMBL20749184 0.74 TAAR1 (0.50) TAAR1CTBP2PTGS1PTGS2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117769759-A Electronic device and method of manufacturing the same 富士胶片株式会社 2024-03-26 — — CN disclosed
CN-117652208-A Electronic device and method of manufacturing the same 富士胶片株式会社 2024-03-05 — — CN disclosed
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. GHSR, IGF1R, GIPR TAAR1 48/4885CTBP2 4394/4885PTGS1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.